Table S2.
PIP decisions wrongly listed under ‘oncology’ by EMA (5 decisions)
| Compound | Indication | PIP number | Until |
|---|---|---|---|
| Alemtuzumab | MS | EMEA-001072-PIP01-10 | SEP2018 |
| MAB (LY2127399) | MS and chronic autoimmune arthritis | EMEA-000802-PIP01-09 | DEC2023 |
| Darbepoetin alfa | Symptomatic anemia associated with chronic renal failure (CRF) | EMEA-000329-PIP02-09-M03 | DEC2016 |
| Briakinumab | Psoriasis vulgaris | EMEA-000552-PIP01-09-M01 | NOV2016 |
| Rituximab | Granulomatosis w. polyangiitis (Wegener’s), microscopic polyangiitis | EMEA-000308-PIP02-11 | MAY2016 |
Abbreviations: MS, multiple sclerosis; PIP, pediatric investigation plan; SEP, September; NOV, November; DEC, December; MAB, monoclonal antibody; EMA, European Medicines Agency.